Last reviewed · How we verify
Insulin lispro 6 day reservoir in-use
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin lispro 6 day reservoir in-use |
|---|---|
| Also known as | LY275585, Humalog |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin lispro is a recombinant human insulin analog with a rapid onset of action, designed to mimic the body's natural insulin response to meals. It binds to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production. The 6-day reservoir formulation extends the duration of action compared to standard insulin lispro, allowing for less frequent dosing.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (PHASE3)
- Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin lispro 6 day reservoir in-use CI brief — competitive landscape report
- Insulin lispro 6 day reservoir in-use updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI